carefusion

The focus this week, at least initially, will no doubt be on the effect of the downgrade of U.S. debt. But there will be plenty more earnings as well, including reports from Walt Disney (NYSE: DIS), News Corp. (NASDAQ: NWS), Cisco Systems (NASDAQ: CSCO) and Aol (NYSE: AOL). The parade of retail...

According to J.P. Morgan, CareFusion (NYSE: CFN) held management meetings. J.P. Morgan said that it spent two days last week traveling with CareFusion CEO Kieran Gallahue and CFO Jim Hinrichs, from which it walked away with increasing confidence in the play out of the CareFusion story both near...

J.P. Morgan is out with its report today on CareFusion (NYSE: CFN), maintaining Overweight. In a note to clients, J.P. Morgan writes, "We are updating our CareFusion model, trimming estimates to reflect ongoing softness in the respiratory business, coupled with near-term conservatism on the...

Deutsche Bank released a report on CareFusion (NYSE: CFN) yesterday. In it, Deutsche Bank noted the mixed results for the company's F3Q11 report. Deutsche Bank writes, “CareFusion reported F3Q11 results that were mixed. Like last quarter, sales were below expectations though EPS beat our and...

J.P. Morgan commented on CareFusion's (NYSE: CFN) Q3 results. In a research report published today, J.P. Morgan portrayed a mixed outlook on CareFusion. In the report, J.P. Morgan states, "CareFusion's 3Q played out largely as expected: the top line was light, but gross margin exceeded...

According to J.P. Morgan, CareFusion (NYSE: CFN) shares are upgraded to Overweight. J.P. Morgan reported that it is upgrading shares of CareFusion to Overweight from Neutral and raising its EPS estimates for 2012 and beyond. “CareFusion is, in our view, a new management and margin expansion story...

JP Morgan has upgraded CareFusion Corporation (NYSE: CFN) from Neutral to Overweight and has raised the price target from $28 to $36.

Citigroup has raised the price target on CareFusion Corporation (NYSE: CFN) from $29 to $31 and maintains its Buy rating.

J.P. Morgan is updating its CareFusion (NYSE: CFN) model to reflect a slightly lower sales outlook and modestly higher SG&A spending. “For FY11, we forecast sales of $4,097M (+4.3%) and EPS of $1.60 (+12.6%),” J.P. Morgan writes. “This compares to management guidance that calls for mid-single-...

Citigroup has published a research report on CareFusion (NYSE: CFN) after the company reported 3Q earnings results slightly below expectations. In the report, Citigroup writes "While results were roughly in-line with our recently revised estimates that did account for several one-time events in...

J.P. Morgan is updating its CareFusion Corporation (NYSE: CFN-WI) model to reflect the weaker dollar as well as a more gradual sales ramp as we move through FY11. “The net of these changes is a $70M increase to our 2011 sales estimate and a $0.02 increase to EPS,” J.P. Morgan writes. “Our new FY11...

Goldman Sachs has initiated coverage on these companies: CareFusion Corp. (NYSE: CFN) Buy Varian Medical Systems (NYSE: VAR) Sell Cemex (NYSE: CX) Neutral

Upgrades: Estacio Participacoes SA (SAO: ESTC3) upgraded from Equal to Overweight, price target remains at $25, 2010 EPS raised to $1.15 (from $1.12), 2011 raised to $1.32 (from $1.15). Downgrades: Adobe Systems (NASDAQ: ADBE) downgraded to Equal from Overweight, price target remains at $42....

Initiation coverage from Deutsche Bank for September 10 is as follows: St. Jude Medical (NYSE: STJ) Initiate with Hold Rating and $39 price target Boston Scientific (NYSE: BSX) Initiate with Hold rating and $6.30 price target. Zimmer Holdings (NYSE: ZMH) Initiate with Hold rating and $53 price...